Background: Autologous vein is the preferred conduit for lower extremity bypass in patients with peripheral arterial disease (PAD) because of its superior patency. However, autologous vein is often unavailable because it has been previously harvested or is of inadequate caliber for a successful bypass. Cryopreserved veins and arteries are being increasingly used in these situations, although the literature reports patency rates inferior to those of both autologous vein and synthetic materials. Consequently, some authors have proposed that cryopreserved conduits should be used only as a last resort or only for critical limb ischemia. Extensive literature demonstrates that numerous cadaveric donor characteristics affect clinical outcomes in organ allotransplantation, but little is known about how donor characteristics affect vascular allotransplantation. Currently, variables having an impact on the patency of cryopreserved conduits remain an understudied area of clinical importance. The purpose of this study was to examine the risk-adjusted impact of cadaveric donor, patient, and operative characteristics on primary patency in patients undergoing lower extremity bypass. We hypothesized that increased warm ischemia times (WITs) would have a negative impact on the primary patency of these bypass grafts.
Methods: Clinical data for all patients who received a cryopreserved femoral artery, vein, or saphenous vein for lower extremity bypass for symptomatic PAD at a single-center institution from 2010 to 2016 were included for analysis. Patients' data were obtained from the institutional Clinical Data Repository and chart review. Allograft donor blood type and WIT were provided by the tissue processing organization. This study was approved by the Institutional Review Board with a waiver of consent because of its retrospective nature. This study's primary outcomes were primary patency and patient survival. Primary patency was defined according to the recommended reporting standards as detailed by Rutherford et al. In short, the graft is considered to have lost primary patency with interruption of flow by any means. Loss of primary patency was determined by objective testing including duplex ultrasound, computed tomography, and angiography; physical examination was not used for this assessment. Preoperative variables of interest were comorbidities, donor blood type, WIT, type of bypass, and use of arterial or venous allograft. Below-the-knee bypasses were classified as those with any infrageniculate target, including femoral below-the-knee popliteal and distal bypasses. Distal bypasses were classified as those to the tibioperoneal trunk and anterior or posterior tibial artery. Continuous variables are presented as mean 6 standard deviation and categorical variables as count (percentage). Patients were stratified by primary patency status for univariate analysis, either t-test or c 2 test as appropriate. In addition, the impact of preoperative variables on time to loss of primary patency was evaluated using Kaplan-Meier analysis. A Cox proportional hazards model was used to determine risk-adjusted associations. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Results: A total of 60 patients with PAD underwent lower extremity bypass with 65 cryopreserved conduits during the study period. Primary patency at 1 year was 26.2%. Types of bypass were categorized into axillary-femoral (n ¼ 5), iliac-femoral (n ¼ 5), femoral-femoral (n ¼ 11), femoral-popliteal (n ¼ 11), popliteal-distal (n ¼ 4), and femoral-distal (n ¼ 29). Average survival was 581.5 6 559.7 days. The most common surgical indication was critical limb ischemia (64.6%; P < .01). Twenty-three 
60).
Conclusions: This study reports the impact of cadaveric donor characteristics on the primary patency of cryopreserved vascular conduits used for lower extremity bypass. These data showed that primary patency decreased as WITs increased (HR, 1.1; P ¼ .02). Popliteal-distal bypasses had the worst primary patency, and bypasses in the femoral-femoral position had superior patency among the study population. These results provide additional insight into using cryopreserved conduits for these procedures. Overall primary patency at 1 year in this study was 26.1%, and this is analogous to other reports. In a series of 35 patients, Walker et al reported 28% patency in the same interval. The largest series to date, including 177 patients and 240 conduits, by Farber et al had a similar rate of 30% at 12 months. The finding of no significant increase in loss of primary patency with differing donor blood types is consistent with that of Walker et al. 4 However, other studies have found outcomes affected by ABO incompatibility. 3, 8 O'Banion et al found that ABO incompatibility was a significant risk factor for 30-day graft failure. Zehr et al reported that only 6 of 20 noncompatible grafts offered limb salvage. In other studies, centers seromatched all donor veins to recipients but did not find a difference between different donor blood type or Rh immunization and patency. 2, [5] [6] [7] Cryopreserved femoral arteries are much more robust tissue than saphenous vein, and the robust patency of arterial conduits compared with venous conduits in cardiac surgery is well known. Only a few studies have reported outcomes with cryopreserved arterial conduits, and these found a high rate of degeneration and loss of patency. In the current study, there was no significant difference in patency between artery and vein, even with below-the-knee bypass. A limitation of this study is that it may have been underpowered to demonstrate statistical significance. Duration of ischemia time is a known variable affecting outcomes in organ allotransplantation. Many techniques are currently used in clinical practice to condition organs that have been subject to extended ischemia times to improve outcomes. Considering this, it may not be surprising that longer ischemia times could affect graft patency from femoral arteries and saphenous veins harvested from cadaveric donors. However, this has not been previously reported in the vascular surgery literature and is a unique finding of the current analysis. Further studies should continue to evaluate the impact of ischemia time on patency to determine whether this factor will continue to have a role in graft patency and survival. Limitations of this study include its retrospective nature with inherent risk of selection bias as well as the limited number of patients (n ¼ 60). Clinical decisions should not be made on the basis of the results of a single study with limited subject numbers. Furthermore, the reported observations are merely associations between donor characteristics and primary patency; this does not imply a direct cause and effect relationship. In addition, the conduit diameters reported herein are from the product insert schematic; it is possible that intraoperative trimming could have affected the accuracy of these measurements. The current results indicate that increased WITs are associated with increased risk-adjusted loss of primary patency of lower extremity bypasses and reflect the outcomes of a single-institution cohort of vascular surgery patients. Larger future analyses related to the impact of donor characteristics on cryopreserved conduits are warranted because of the potential to significantly affect patient outcomes.
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The Implementation of a Pulmonary Embolism Response Team in the Management of Pulmonary Embolism
Eleftherios S. Xenos, George Davis, Amanda Green, Qiang He, Susan Smyth. University of Kentucky Medical Center, Lexington, Ky Background: Massive and submassive pulmonary embolism (PE) can be life-threatening. Management options include anticoagulation, systemic fibrinolysis, and interventional treatment with catheter-directed or open surgical thrombus removal with or without extracorporeal membrane oxygenation. Currently, most patients with PE, even if they are hemodynamically unstable, are treated with anticoagulation alone. With increasing patient complexity and several therapeutic options, the optimal approach for patients with intermediate-to highrisk PE is not clearly established. The implementation of a clinical pathway executed by a multidisciplinary, rapid response team can optimize risk stratification and expedite management. To this end, the PE response team (PERT) was created at our institution with specialists from vascular surgery, critical care, interventional radiology, emergency medicine, cardiac surgery, and cardiology. The team used current evidence, knowledge, and recommendations as well as institutional experience to reach consensus and to create a risk stratification and treatment algorithm for management of patients with massive and submassive PE. The team is organized as a rapid response team and is activated with a 24-hour telephone number to evaluate and to treat these patients using the algorithm. We review our initial experience with this approach.
Methods: The records of patients who were treated by the PERT in 2016 (inception late 2015) and 2017 were reviewed (intervention group). The diagnosis codes of these patients were retrieved from the Vizient database, and a retrospective control cohort group was created using 
